Ascendis Pharma A/S (ASND) – Research Analysts’ Recent Ratings Updates

Ascendis Pharma A/S (NASDAQ: ASND) has recently received a number of price target changes and ratings updates:

• 11/20/2024 – Ascendis Pharma A/S was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/15/2024 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
• 11/15/2024 – Ascendis Pharma A/S had its price target lowered by analysts at Oppenheimer Holdings Inc. from $190.00 to $180.00. They now have an “outperform” rating on the stock.
• 11/15/2024 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
• 11/15/2024 – Ascendis Pharma A/S had its price target lowered by analysts at TD Cowen from $160.00 to $153.00. They now have a “buy” rating on the stock.
• 11/15/2024 – Ascendis Pharma A/S had its price target raised by analysts at Stifel Nicolaus from $200.00 to $207.00. They now have a “buy” rating on the stock.
• 11/12/2024 – Ascendis Pharma A/S was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/4/2024 – Ascendis Pharma A/S was upgraded by analysts at Wedbush to a “strong-buy” rating.
• 11/4/2024 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
• 10/23/2024 – Ascendis Pharma A/S had its price target lowered by analysts at JPMorgan Chase & Co. from $180.00 to $174.00. They now have an “overweight” rating on the stock.
• 10/21/2024 – Ascendis Pharma A/S had its price target raised by analysts at TD Cowen from $157.00 to $160.00. They now have a “buy” rating on the stock.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $134.60 on Wednesday. The business has a fifty day simple moving average of $133.04 and a two-hundred day simple moving average of $132.17. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The company has a market capitalization of $8.16 billion, a P/E ratio of -16.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of the company. Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares in the last quarter. Finally, Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at $60,000.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.